A Hundred Drugs Contend: Chinese Biopharma Gains US Foothold
Two China-Discovered Cancer Treatments May Win US FDA Approval This Year
Executive Summary
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.
You may also be interested in...
EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
Keeping Track: First COVID Vaccine BLA Kicks Off; Oncology Submissions From Hutchmed, Takeda And Shorla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.